Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
Doshi SD, Knezevic A, Gonzalez C, Fischer P, Goodman R, Gornell S, Patel S, Puzio C, Ritea A, Lee CH, Evans L, Voss MH, Motzer RJ, Kotecha RR. Doshi SD, et al. Among authors: kotecha rr. Clin Genitourin Cancer. 2025 Feb;23(1):102268. doi: 10.1016/j.clgc.2024.102268. Epub 2024 Nov 13. Clin Genitourin Cancer. 2025. PMID: 39616970
Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.
Khaleel S, Perera M, Papa N, Kuo F, Golkaram M, Rappold P, Kotecha RR, Coleman J, Russo P, Motzer R, Reznik E, Hakimi AA. Khaleel S, et al. Among authors: kotecha rr. Urol Oncol. 2024 Nov 12:S1078-1439(24)00694-X. doi: 10.1016/j.urolonc.2024.10.013. Online ahead of print. Urol Oncol. 2024. PMID: 39537440
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Fitzgerald KN, et al. Among authors: kotecha rr. Eur Urol. 2025 Jan;87(1):96. doi: 10.1016/j.eururo.2024.10.002. Epub 2024 Oct 18. Eur Urol. 2025. PMID: 39426859 No abstract available.
Sample Site Impacts RNA Biomarkers for Renal Cell Carcinoma.
Eismann L, Xie AX, Tang C, Knezevic A, Ostrovnaya I, Kuo F, Ari Hakimi A, Reznik E, Kotecha RR. Eismann L, et al. Among authors: kotecha rr. Eur Urol. 2025 Jan;87(1):79-83. doi: 10.1016/j.eururo.2024.09.004. Epub 2024 Oct 2. Eur Urol. 2025. PMID: 39358058 Free article.
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery.
Ma J, Del Balzo L, Walch H, Khaleel S, Knezevic A, Flynn J, Zhang Z, Eichholz J, Doshi SD, Voss MH, Freeman B, Ari Hakimi A, Lee CH, Bale TA, Kelly D, Mueller BA, Mann J, Yu Y, Zinovoy M, Chen L, Cuaron J, Khan A, Yamada Y, Shin JY, Beal K, Moss NS, Carlo MI, Motzer RJ, Imber BS, Kotecha RR, Pike LRG. Ma J, et al. Among authors: kotecha rr. Eur Urol Oncol. 2024 Aug 5:S2588-9311(24)00178-0. doi: 10.1016/j.euo.2024.07.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39107179
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Fitzgerald KN, et al. Among authors: kotecha rr. Eur Urol. 2024 Aug;86(2):90-94. doi: 10.1016/j.eururo.2024.04.025. Epub 2024 May 22. Eur Urol. 2024. PMID: 38782695 Clinical Trial.
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma.
Reese SW, Eismann L, White C, Villada JA, Khaleel S, Ostrovnaya I, Vazquez-Rivera K, Carlo MI, Feldman D, Lee CH, Motzer R, Voss MH, Kotecha RR, Matulewicz RS, Goh A, Coleman J, Russo P, Hakimi AA. Reese SW, et al. Among authors: kotecha rr. Urol Oncol. 2024 Feb;42(2):32.e9-32.e16. doi: 10.1016/j.urolonc.2023.12.003. Epub 2023 Dec 21. Urol Oncol. 2024. PMID: 38135627
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Kotecha RR, Doshi SD, Knezevic A, Chaim J, Chen Y, Jacobi R, Zucker M, Reznik E, McHugh D, Shah NJ, Feld E, Aggen DH, Rafelson W, Xiao H, Carlo MI, Feldman DR, Lee CH, Motzer RJ, Voss MH. Kotecha RR, et al. Eur Urol Oncol. 2024 Aug;7(4):804-811. doi: 10.1016/j.euo.2023.10.017. Epub 2023 Nov 7. Eur Urol Oncol. 2024. PMID: 37945488 Clinical Trial.
42 results